GleamWall
中文EN

PRQR ProQR Therapeutics N.V. IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1612940 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-15.9%
TTM net income YoY-51.9%
TTM EPS YoY-25.0%
Revenue 3-yr CAGR64.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-273.1%
Net margin-265.2%
FCF margin-338.3%
EBITDA margin—

Returns

ROE-61.2%
ROA-30.1%
ROIC (approx.)—
Asset turnover0.11x

Leverage & solvency

Liabilities / assets56.2%
Debt / equity0.00x
Current ratio3.09x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.25x
Accruals ratio7.6%
Payout ratio—
Capex / revenue6.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY20252025-12-31FY20242024-12-31
Income statement
Revenue15.91M18.91M
R&D expense44.73M36.36M
SG&A expense15.06M13.66M
Operating income-43.45M-30.47M
Interest expense929,0001.08M
Pretax income-42.16M-27.96M
Income tax19,000-197,000
Net income-42.18M-27.76M
EPS (basic)-0.40-0.32
EPS (diluted)-0.40-0.32
Weighted avg. shares (diluted)105.33M86.09M
Balance sheet
Cash & equivalents92.41M149.41M
Receivables6.80M3.75M
Current assets100.13M153.84M
PP&E, netmay include right-of-use assets (IFRS)12.63M14.11M
Total assets112.76M167.96M
Current liabilities32.44M38.90M
Short-term debt4.87M4.58M
Total liabilities63.38M79.40M
Shareholders' equity49.37M88.56M
Cash flow statement
Operating cash flow-52.79M-36.39M
Capital expenditure1.02M1.42M
Free cash flow-53.81M-37.81M
Investing cash flow-1.02M-4.07M
Financing cash flow-1.84M70.28M
Stock-based compensation4.01M2.54M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.